[Invasive aspergillosis: clinical manifestations and treatment].
Lumbreras
Carlos
C
Unidad de Enfermedades Infecciosas, Hospital Universitario Doce de Octubre, Universidad Complutense de Madrid, Madrid, Spain. clumbrerasb@medynet.com
Gavaldá
Joan
J
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis / Q000188:drug therapy; D000077336:Caspofungin; D003881:Dermatomycoses / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D004359:Drug Therapy, Combination; D054714:Echinocandins; D006801:Humans; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use; D055666:Lipopeptides; D020953:Neuroaspergillosis / Q000175:diagnosis / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications; D010455:Peptides / Q000627:therapeutic use; D010456:Peptides, Cyclic; D011743:Pyrimidines / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D007155:Immunologic Factors; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B; D000077336:Caspofungin; D065819:Voriconazole
Aspergilosis invasora: manifestaciones clínicas y tratamiento.